Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Loibl S, Tang G, Nekljudova V, Rastogi P, Rachakonda S, Reinisch M, Acosta J, Schneeweiss A, Hilton C, Seiler S, Bhargava R, Karn T, Cortazar P, Moreno F, Andersen J, Christensen S, Klare P, Murali S, Morales S, Huober J, Boileau JF, Rodríguez-Lescure Á, Boudreau D, Polewski PJ, Teply-Szymanski J, Mouta J, Mamounas EP, Denkert C, Wolmark N, Geyer CE.

Open source

DOI: 10.1038/s41591-026-04565-6
Published: 2026-09-01
Container: Nat Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04565-6,
  title = {Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.},
  author = {Loibl S and  Tang G and  Nekljudova V and  Rastogi P and  Rachakonda S and  Reinisch M and  Acosta J and  Schneeweiss A and  Hilton C and  Seiler S and  Bhargava R and  Karn T and  Cortazar P and  Moreno F and  Andersen J and  Christensen S and  Klare P and  Murali S and  Morales S and  Huober J and  Boileau JF and  Rodríguez-Lescure Á and  Boudreau D and  Polewski PJ and  Teply-Szymanski J and  Mouta J and  Mamounas EP and  Denkert C and  Wolmark N and  Geyer CE.},
  year = {2026},
  journal = {Nat Med},
  doi = {10.1038/s41591-026-04565-6},
  url = {https://doi.org/10.1038/s41591-026-04565-6}
}

RIS

TY  - JOUR
TI  - Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
AU  - Loibl S
AU  -  Tang G
AU  -  Nekljudova V
AU  -  Rastogi P
AU  -  Rachakonda S
AU  -  Reinisch M
AU  -  Acosta J
AU  -  Schneeweiss A
AU  -  Hilton C
AU  -  Seiler S
AU  -  Bhargava R
AU  -  Karn T
AU  -  Cortazar P
AU  -  Moreno F
AU  -  Andersen J
AU  -  Christensen S
AU  -  Klare P
AU  -  Murali S
AU  -  Morales S
AU  -  Huober J
AU  -  Boileau JF
AU  -  Rodríguez-Lescure Á
AU  -  Boudreau D
AU  -  Polewski PJ
AU  -  Teply-Szymanski J
AU  -  Mouta J
AU  -  Mamounas EP
AU  -  Denkert C
AU  -  Wolmark N
AU  -  Geyer CE.
PY  - 2026
JO  - Nat Med
DO  - 10.1038/s41591-026-04565-6
UR  - https://doi.org/10.1038/s41591-026-04565-6
ER  -

APA

S, L., G, T., V, N., P, R., S, R., M, R., J, A., A, S., C, H., S, S., R, B., T, K., P, C., F, M., J, A., S, C., P, K., S, M., S, M., J, H., JF, B., Á, R., D, B., PJ, P., J, T., J, M., EP, M., C, D., N, W., & CE., G. (2026). Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.. Nat Med. https://doi.org/10.1038/s41591-026-04565-6

Source records

europe-pmc · retrieved 2026-09-25T10:52:49.379Z